Mostrar el registro sencillo del ítem
dc.contributor.author
Kamran, Neha
dc.contributor.author
Calinescu, Alexandra
dc.contributor.author
Candolfi, Marianela
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.contributor.author
Chandran, Mayuri
dc.contributor.author
Mineharu, Yohei
dc.contributor.author
Asad, Antonela Sofía
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.contributor.author
Koschmann, Carl
dc.contributor.author
Nunez, Felipe
dc.contributor.author
Lowenstein, Pedro R.
dc.contributor.author
Castro, Maria Gabriela
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.date.available
2018-07-10T18:27:55Z
dc.date.issued
2016-10
dc.identifier.citation
Kamran, Neha; Calinescu, Alexandra; Candolfi, Marianela; Chandran, Mayuri; Mineharu, Yohei; et al.; Recent advances and future of immunotherapy for glioblastoma; Informa Healthcare; Expert Opinion on Biological Therapy; 16; 10; 10-2016; 1245-1264
dc.identifier.issn
1471-2598
dc.identifier.uri
http://hdl.handle.net/11336/51640
dc.description.abstract
Introduction: Outcome for glioma (GBM) remains dismal despite advances in therapeutic interventions including chemotherapy, radiotherapy and surgical resection. The overall survival benefit observed with immunotherapies in cancers such as melanoma and prostate cancer has fuelled research into evaluating immunotherapies for GBM. Areas covered: Preclinical studies have brought a wealth of information for improving the prognosis of GBM and multiple clinical studies are evaluating a wide array of immunotherapies for GBM patients. This review highlights advances in the development of immunotherapeutic approaches. We discuss the strategies and outcomes of active and passive immunotherapies for GBM including vaccination strategies, gene therapy, check point blockade and adoptive T cell therapies. We also focus on immunoediting and tumor neoantigens that can impact the efficacy of immunotherapies. Expert opinion: Encouraging results have been observed with immunotherapeutic strategies; some clinical trials are reaching phase III. Significant progress has been made in unraveling the molecular and genetic heterogeneity of GBM and its implications to disease prognosis. There is now consensus related to the critical need to incorporate tumor heterogeneity into the design of therapeutic approaches. Recent data also indicates that an efficacious treatment strategy will need to be combinatorial and personalized to the tumor genetic signature.
dc.format
application/pdf
dc.language.iso
eng
dc.publisher
Informa Healthcare
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.rights
info:eu-repo/semantics/openAccess
dc.rights.uri
https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
dc.subject
Cancer Vaccines
dc.subject
Checkpoint Blockade
dc.subject
Gene Therapy
dc.subject
Glioma
dc.subject
Immunotherapy
dc.subject
Passive Immunotherapy
dc.subject.classification
Inmunología
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.subject.classification
Medicina Básica
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.title
Recent advances and future of immunotherapy for glioblastoma
dc.type
info:eu-repo/semantics/article
dc.type
info:ar-repo/semantics/artículo
dc.type
info:eu-repo/semantics/publishedVersion
dc.date.updated
2018-06-06T13:40:19Z
dc.journal.volume
16
dc.journal.number
10
dc.journal.pagination
1245-1264
dc.journal.pais
Reino Unido
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.journal.ciudad
London
dc.description.fil
Fil: Kamran, Neha. University of Michigan; Estados Unidos
dc.description.fil
Fil: Calinescu, Alexandra. University of Michigan; Estados Unidos
dc.description.fil
Fil: Candolfi, Marianela. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas; Argentina
dc.description.fil
Fil: Chandran, Mayuri. University of Michigan; Estados Unidos
dc.description.fil
Fil: Mineharu, Yohei. Kyoto University; Japón
dc.description.fil
Fil: Asad, Antonela Sofía. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas; Argentina
dc.description.fil
Fil: Koschmann, Carl. University of Michigan; Estados Unidos
dc.description.fil
Fil: Nunez, Felipe. University of Michigan; Estados Unidos
dc.description.fil
Fil: Lowenstein, Pedro R.. University of Michigan; Estados Unidos
dc.description.fil
Fil: Castro, Maria Gabriela. University of Michigan; Estados Unidos
dc.journal.title
Expert Opinion on Biological Therapy
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://www.tandfonline.com/doi/full/10.1080/14712598.2016.1212012
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1080/14712598.2016.1212012
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5014608/
Archivos asociados